Spironolactone Noninferior in Duchenne Muscular Dystrophy
MONDAY, Oct. 28, 2019 -- In a head-to-head study of mineralocorticoid receptor antagonists, spironolactone was found to be noninferior to eplerenone for slowing the progression of heart damage in boys with Duchenne muscular dystrophy (DMD),...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Boys | Cardiology | Heart | Muscular Dystrophy | Pharmaceuticals | Reflex Sympathetic Dystrophy | Spironolactone | Study